Paul Bryson

Paul Bryson, PhD, is currently the Executive Director at CSL Behring, leading the Cell & Gene Therapy platform. With extensive experience in genetic medicine, they previously served as Senior Director and Head of US Operations at TCRCure Biopharma Corp., overseeing TCR-T and CAR-T product development. Paul has held research positions at prestigious institutions such as the University of Southern California and Baylor College of Medicine, focusing on innovative approaches in immunotherapy and viral research. They earned their PhD in Microbiology & Immunology from Stanford University and an AB in Molecular Biology from Princeton University.